VYGR [NASD]
Voyager Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.88 Insider Own1.00% Shs Outstand38.05M Perf Week-7.77%
Market Cap233.35M Forward P/E- EPS next Y-1.64 Insider Trans-6.80% Shs Float32.94M Perf Month-22.54%
Income-70.90M PEG- EPS next Q-0.32 Inst Own56.90% Short Float3.95% Perf Quarter68.99%
Sales31.60M P/S7.38 EPS this Y-292.10% Inst Trans20.38% Short Ratio1.52 Perf Half Y98.36%
Book/sh2.00 P/B3.03 EPS next Y1.80% ROA-34.90% Target Price6.60 Perf Year49.75%
Cash/sh4.33 P/C1.40 EPS next 5Y- ROE-76.80% 52W Range2.46 - 10.60 Perf YTD123.25%
Dividend- P/FCF259.28 EPS past 5Y-3.50% ROI- 52W High-42.92% Beta1.12
Dividend %- Quick Ratio1.70 Sales past 5Y21.30% Gross Margin- 52W Low145.93% ATR0.75
Employees101 Current Ratio1.70 Sales Q/Q-89.20% Oper. Margin- RSI (14)41.41 Volatility5.76% 9.53%
OptionableYes Debt/Eq0.00 EPS Q/Q2.90% Profit Margin- Rel Volume0.18 Prev Close6.13
ShortableYes LT Debt/Eq0.00 EarningsMay 04 AMC Payout- Avg Volume857.00K Price6.05
Recom2.40 SMA20-10.59% SMA50-21.22% SMA20036.68% Volume154,755 Change-1.31%
Oct-07-21Upgrade Robert W. Baird Neutral → Outperform $6 → $9
Feb-26-21Downgrade Robert W. Baird Outperform → Neutral $18 → $6
Feb-03-21Downgrade Wedbush Outperform → Neutral $6
Feb-03-21Downgrade BTIG Research Buy → Neutral
Dec-24-20Downgrade Cantor Fitzgerald Overweight → Neutral $15 → $10
Dec-23-20Downgrade Raymond James Outperform → Mkt Perform
Nov-11-20Downgrade Oppenheimer Outperform → Perform
Nov-10-20Downgrade Wells Fargo Overweight → Equal Weight $10
Nov-10-20Downgrade Raymond James Strong Buy → Outperform $28 → $17
Mar-19-20Initiated The Benchmark Company Buy $18
Feb-06-20Initiated Oppenheimer Outperform
Nov-15-18Upgrade Raymond James Outperform → Strong Buy
Sep-10-18Resumed BTIG Research Buy $32
Sep-10-18Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-04-18Initiated H.C. Wainwright Buy $30
Mar-12-18Downgrade Wedbush Outperform → Neutral $29
Mar-12-18Downgrade Evercore ISI Outperform → In-line
Feb-02-18Initiated Morgan Stanley Overweight
Nov-28-17Resumed Piper Jaffray Overweight $28
Oct-31-17Initiated Robert W. Baird Outperform $31
May-19-22 08:38AM  
06:00AM  
May-16-22 06:00AM  
May-04-22 05:35PM  
04:01PM  
01:22PM  
May-03-22 07:00AM  
May-02-22 11:04AM  
Apr-25-22 02:51PM  
Apr-22-22 01:19PM  
11:36AM  
Apr-21-22 07:28AM  
Apr-20-22 10:19AM  
Apr-18-22 12:45PM  
Apr-12-22 02:57PM  
11:57AM  
11:47AM  
Apr-08-22 12:26PM  
11:39AM  
Apr-07-22 02:50PM  
Apr-06-22 12:08PM  
11:58AM  
Apr-01-22 12:00PM  
Mar-30-22 07:43AM  
Mar-26-22 06:11AM  
Mar-23-22 11:40AM  
08:42AM  
08:28AM  
Mar-22-22 10:52AM  
09:07AM  
07:00AM  
Mar-19-22 06:05AM  
Mar-17-22 09:47AM  
Mar-15-22 11:13AM  
10:52AM  
10:00AM  
Mar-10-22 02:31PM  
12:27PM  
Mar-09-22 12:54PM  
12:35PM  
Mar-08-22 02:20PM  
08:30AM  
06:27AM  
06:16AM  
01:15AM  
Mar-07-22 09:15AM  
Mar-01-22 05:55PM  
Feb-22-22 04:35AM  
Feb-17-22 03:03PM  
Feb-10-22 07:00AM  
Feb-03-22 07:00AM  
Jan-26-22 05:15PM  
Dec-14-21 01:25PM  
Nov-19-21 07:30AM  
Nov-17-21 03:01AM  
Nov-16-21 07:00AM  
Nov-02-21 08:25AM  
07:00AM  
Nov-01-21 03:02PM  
Oct-20-21 08:54AM  
Oct-14-21 11:30AM  
Oct-07-21 12:55PM  
10:23AM  
08:30AM  
Oct-06-21 12:37PM  
12:08PM  
10:23AM  
10:18AM  
08:01AM  
07:32AM  
07:00AM  
Sep-02-21 05:08PM  
Aug-15-21 04:14AM  
Aug-10-21 04:20PM  
Aug-09-21 08:25AM  
07:00AM  
Aug-02-21 03:01PM  
Jun-30-21 07:58AM  
May-19-21 04:01PM  
May-12-21 10:20AM  
07:30AM  
May-11-21 07:30AM  
May-10-21 08:45AM  
07:30AM  
Apr-29-21 10:50AM  
Apr-28-21 12:33PM  
08:00AM  
Apr-27-21 10:10AM  
08:05AM  
Apr-26-21 09:32AM  
08:00AM  
Apr-20-21 10:51AM  
Mar-24-21 10:08AM  
10:00AM  
02:10AM  
Mar-23-21 06:45PM  
06:05PM  
01:00PM  
08:30AM  
Mar-22-21 01:00PM  
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Swartz RobinChief Operating OfficerApr 04Sale8.251,52712,59852,060Apr 06 04:34 PM
Hesslein Robert W.Senior VP & General CounselApr 04Sale8.252,78622,984114,963Apr 06 04:34 PM
Swartz RobinChief Operating OfficerMar 21Sale8.294,41336,60453,587Mar 23 06:40 PM
Hesslein Robert W.Senior VP & General CounselMar 21Sale8.294,95541,100117,749Mar 23 06:39 PM
Burek JulieVP, FinanceMar 21Sale8.292,64921,97252,458Mar 23 06:36 PM
Burek JulieVP, FinanceFeb 17Sale3.557892,80155,107Feb 22 04:35 PM
Hesslein Robert W.Senior VP & General CounselFeb 17Sale3.554,10014,555122,704Feb 22 04:37 PM
Hesslein Robert W.Senior VP & General CounselFeb 11Sale3.363,25210,927126,804Feb 15 04:42 PM
Burek JulieVP, FinanceFeb 11Sale3.363611,21355,896Feb 15 04:40 PM
Burek JulieVP, FinanceJan 12Sale3.0626581146,257Jan 14 06:14 PM
Burek JulieVP, FinanceJan 03Sale2.833,0638,66846,522Jan 14 06:14 PM